A phase II study of CLAG regimen in combination with imatinib mesylate (Gleevec) in refractory or relapsed Acute Myeloid leukemia.

Trial Profile

A phase II study of CLAG regimen in combination with imatinib mesylate (Gleevec) in refractory or relapsed Acute Myeloid leukemia.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2014

At a glance

  • Drugs Imatinib (Primary) ; Cladribine; Cytarabine; Filgrastim
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 17 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 18 Apr 2014 Planned End Date changed from 1 May 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top